Table 2.

Characteristics of patients with nonfatal coronary artery disease event and matched controls

	Cases occurring in the first year of follow-up and their controls			Cases occurring after 1 year of follow-up and their controls
	Cases	Controls	P-value*	Cases	Controls	P-value*
Number	958	19 160		580	11 600
Age (years) (continuous)†	58 (±5)	58 (±5)	0.11	58 (±5)	58 (±5)	0.21
Mean equivalent dose‡	19 (±13)	18 (±11)	0.01	16 (±11)	16 (±10)	0.78
Statin adherence (%)§ (yes vs. no)
< 90%	35	36	0.41	67	63	0.06
≥90%	65	64		33	37
Sex (male vs. female) (%)	43	37	0.001	41	35	0.004
Social assistance (yes vs. no) (%)†	34	29	0.003	38	33	0.01
Diabetes (%)	21	19	0.039	22	19	0.031
Newly diagnosed diabetes mellitus¶ (yes vs. no)	6	4		3	2
Antidiabetic drug adherence < 80%** (yes vs. no)	7	7		11	9
Antidiabetic drug adherence ≥80%** (yes vs. no)	8	8		9	9
Hypertension (%)	62	46	< 0.0001	65	50	< 0.0001
Newly diagnosed hypertension¶ (yes vs. no)	20	12		11	5
Antihypertensive drug adherence < 80%** (yes vs. no)	17	15		25	20
Antihypertensive drug adherence ≥80%** (yes vs. no)	25	20		29	26

^*The P-values are related to analyses made to compare cases with controls.

^†At treatment initiation.

^‡Statins equivalence in simvastatin dose during the follow-up time [46]. Simvastatin 10 mg = lovastatin 20 mg = pravastatin 20 mg = fluvastatin 40 mg = atorvastatin 5 mg.

^§Proportion of days covered (%).

^¶ICD-9 or pharmacological treatment; new diabetes or new hypertension were detected in the year before the index date.

^**Proportion of days covered (%) in the year before the index date.